A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 41,13 (-11,64%). A mediana é € 40,12 (-13,81%).

Comprar	5
Manter	1
Vender	0

Notícias Ir para o feed de notícias

HeartFlow: plaque analysis becomes main growth driver

HeartFlow presented plaque analysis as its most important near-term growth driver at the Wells Fargo conference and projects about $30 million in revenue for 2026 versus $1.5 million in 2025. In Q2 2026 revenue rose 48% to over $64 million with a gross margin of roughly 82%. The company has about $250 million in cash, aims for profitability by mid-2028, and sees an expanded addressable market from $5 billion to $11 billion through expansion into asymptomatic high-risk patients; a broader product rollout including PCI Navigator is planned for 2027. » Mais em de.investing.com
Heartflow climbs to new record high of $51.26

Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » Mais em de.investing.com
Heartflow hits record high of $48.70 after strong Q2 results

Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, HeartFlow registou receitas de € 56,15 mi e um ganho líquido de -€ 13,79 mi

(EUR)	junho de 2026	YoY
Receitas	56,15 mi	52,41%
Ganho bruto	46,61 mi	67,59%
Ganho líquido	-13,79 mi	76,80%
EBITDA	-13,77 mi	4.276,26%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 3,79 bi
Número de ações	86,24 mi
Máximo/mínimo de 52 semanas	€ 46,55 - € 17,95
Dividendos	Não
Beta	2,02
PER (PE Ratio)	-34,73
PEG (PEG Ratio)	4,81
P/VC (PB Ratio)	15,23
P/V (PS Ratio)	20,06

Perfil da empresa

HeartFlow, Inc. ist ein Medizintechnikunternehmen, das weltweit nicht-invasive Lösungen für die Diagnose und Behandlung von Koronararterienerkrankungen anbietet. Seine HeartFlow-Plattform nutzt KI und numerische Strömungsmechanismen, um aus einer einzigen Koronar-Computertomographie-Angiographie, einer speziellen Art von Scan, der detaillierte Bilder der Herzarterien liefert, ein personalisiertes 3D-Modell des Herzens eines Patienten zu erstellen. Die Plattform des Unternehmens bietet Einblicke in den Blutfluss, die Verengung sowie das Volumen und die Zusammensetzung von Plaque, indem sie die Einschränkungen herkömmlicher nicht-invasiver Bildgebungstests überwindet. Das Unternehmen wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in Mountain View, Kalifornien.